Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.08M | 1.30M | 1.37M | 1.74M | 1.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.08M | 1.30M | 1.37M | 1.74M | 1.91M |
| Cost of Revenue | 24.39M | 24.70M | 9.50M | 25.84M | 27.43M |
| Gross Profit | -22.31M | -23.40M | -8.13M | -24.10M | -25.52M |
| SG&A Expenses | 8.83M | 9.60M | 25.50M | 10.64M | 11.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.22M | 34.30M | 34.99M | 36.48M | 38.88M |
| Operating Income | -31.13M | -33.00M | -33.62M | -34.74M | -36.97M |
| Income Before Tax | -30.16M | -31.21M | -32.37M | -32.25M | -34.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.16M | -31.21M | -32.37M | -32.25M | -34.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.16M | -31.21M | -32.37M | -32.25M | -34.07M |
| EBIT | -31.13M | -33.00M | -33.62M | -34.74M | -36.97M |
| EBITDA | -28.35M | -30.08M | -30.56M | -31.51M | -33.69M |
| EPS Basic | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 |
| Normalized Basic EPS | -0.16 | -0.16 | -0.16 | -0.17 | -0.18 |
| EPS Diluted | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 |
| Normalized Diluted EPS | -0.16 | -0.16 | -0.16 | -0.17 | -0.18 |
| Average Basic Shares Outstanding | 120.40M | 120.03M | 119.25M | 119.00M | 118.53M |
| Average Diluted Shares Outstanding | 120.40M | 120.03M | 119.25M | 119.00M | 118.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |